Clinical Trials
2 trialsNCT03267186 2023-08-01
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant
Stanford University
Phase 2 Completed
NCT02129062 2017-01-16
Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated